PE68099A1 - Productos particulados - Google Patents
Productos particuladosInfo
- Publication number
- PE68099A1 PE68099A1 PE1998000323A PE00032398A PE68099A1 PE 68099 A1 PE68099 A1 PE 68099A1 PE 1998000323 A PE1998000323 A PE 1998000323A PE 00032398 A PE00032398 A PE 00032398A PE 68099 A1 PE68099 A1 PE 68099A1
- Authority
- PE
- Peru
- Prior art keywords
- refers
- fluticasone propionate
- ortorombic
- hydroxypropilcellulose
- cointroduction
- Prior art date
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 229960000289 fluticasone propionate Drugs 0.000 abstract 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000428 dust Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Disintegrating Or Milling (AREA)
- Formation And Processing Of Food Products (AREA)
Abstract
SE REFIERE A PROPIONATO DE FLUTICASONA CARACTERIZADO POR a)FORMA CRISTALINA ORTOROMBICA; b)DENSIDAD APARENTE DINAMICA DE MENOS DE 0.2 g/cm3, EN PARTICULAR 0,05 g/cm3 Y 0,17 g/cm3; c)TAMANO DE PARTICULA EN EL INTERVALO 1-10 MICRONES; d)COEFICIENTE DE UNIFORMIDAD DE 1-20; e)COHESIVIDAD DE 0-20% EN PARTICULAR DE 0-10%; f)PATRON DE DIFRACCION DE POLVO POR RAYOS X. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION QUE COMPRENDE: LA COINTRODUCCION DE UN FLUIDO SUPERCRITICO (FSC), EN PARTICULAR CO2 Y UN VEHICULO QUE CONTIENE PROPIONATO DE FLUTICASONA EN SOLUCION O SUSPENSION EN UN RECIPIENTE DE FORMACION DE PARTICULAS CON PRESION Y TEMPERATURA CONTROLADAS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA CARACTERIZADA PORQUE UTILIZA COMO PORTADOR DIOXIDO DE SILICIO, HIDROXIPROPILCELULOSA, LACTOSA; ADEMAS SU FORMA DE PRESENTACION DE POLVO SECO O DE ROCIO ES ADECUADO PARA LA INHALACION. EL COMPUESTO PUEDE SER UTIL PARA EL TRATAMIENTO DE PADECIMIENTO RESPIRATORIO COMO ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9622173.4A GB9622173D0 (en) | 1996-10-24 | 1996-10-24 | Particulate Products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE68099A1 true PE68099A1 (es) | 1999-07-19 |
Family
ID=10801903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000323A PE68099A1 (es) | 1996-10-24 | 1998-04-28 | Productos particulados |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6406718B1 (es) |
| EP (1) | EP0937100B1 (es) |
| JP (1) | JP2001502350A (es) |
| AT (1) | ATE240345T1 (es) |
| AU (1) | AU4717197A (es) |
| CA (1) | CA2269134C (es) |
| DE (1) | DE69722023T2 (es) |
| DK (1) | DK0937100T3 (es) |
| ES (1) | ES2198555T3 (es) |
| GB (1) | GB9622173D0 (es) |
| PE (1) | PE68099A1 (es) |
| PT (1) | PT937100E (es) |
| WO (1) | WO1998017676A1 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9806462D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
| GB9828204D0 (en) * | 1998-12-21 | 1999-02-17 | Smithkline Beecham Plc | Process |
| US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
| US20020133032A1 (en) * | 2000-02-25 | 2002-09-19 | Jufang Barkalow | Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| OA12394A (en) | 2000-08-05 | 2004-07-09 | Glaxo Group Ltd | 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent. |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| GB0021927D0 (en) * | 2000-09-07 | 2000-10-25 | Glaxo Group Ltd | Use of pharmaceutical combination |
| GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| BR0213155A (pt) * | 2001-10-10 | 2004-09-14 | Boehringer Ingelheim Pharma | Processamento de pó com fluidos gasosos pressurizados |
| GB0125604D0 (en) * | 2001-10-25 | 2001-12-19 | Glaxo Group Ltd | Novel process |
| AU2003210517A1 (en) * | 2002-02-04 | 2003-09-02 | Elan Pharma International, Ltd. | Drug nanoparticles with lysozyme surface stabiliser |
| GB0202564D0 (en) * | 2002-02-04 | 2002-03-20 | Glaxo Group Ltd | Process |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
| US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
| US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| EP1624862B1 (en) | 2003-05-08 | 2014-12-31 | Nektar Therapeutics | Particulate materials |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
| WO2007009164A1 (en) | 2005-07-15 | 2007-01-25 | Eiffel Technologies Limited | Method of particle formation |
| US10137083B2 (en) | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| CA2645080A1 (en) * | 2006-03-07 | 2007-09-13 | Novavax,Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
| US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| KR20080105174A (ko) * | 2006-04-03 | 2008-12-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약물 미립자 |
| WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
| US20080138409A1 (en) * | 2006-09-29 | 2008-06-12 | Osinga Niels J | Olanzapine pharmaceutical composition |
| GB0702402D0 (en) | 2007-02-08 | 2007-03-21 | Thar Pharmaceuticals Inc | Method of creating crystalline substances |
| CA2677838C (en) | 2007-02-11 | 2017-08-01 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| US8088824B2 (en) * | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| JP2010111592A (ja) * | 2008-11-04 | 2010-05-20 | Aska Pharmaceutical Co Ltd | プロピオン酸フルチカゾンを含む局所投与剤 |
| EP2435027B1 (en) | 2009-05-27 | 2016-10-05 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions |
| US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
| MX350838B (es) | 2011-02-11 | 2017-09-18 | Grain Proc Corporation * | Composicion de sal. |
| AU2012282936B2 (en) * | 2011-07-08 | 2016-11-10 | Pfizer Limited | Process for the preparation of fluticasone propionate form 1 |
| EP2802314B1 (en) * | 2012-01-13 | 2020-11-25 | XSpray Microparticles AB | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP2847207B1 (en) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Fluticasone propionate nanocrystals |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| CN104004044A (zh) * | 2013-02-25 | 2014-08-27 | 武汉诺安药业有限公司 | 高纯度丙酸氟替卡松制备方法 |
| EP3508196B1 (en) | 2014-08-18 | 2021-07-14 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| CN108066329B (zh) * | 2016-11-11 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吸入用氟替卡松或其衍生物的微粒的制备方法 |
| WO2021219230A1 (en) | 2020-04-30 | 2021-11-04 | Paolo Fiorina | Antiviral treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1291A (en) | 1980-02-15 | 1985-10-18 | Glaxo Group Ltd | Androstane 17 beta carbothioates |
| JPS56138200A (en) * | 1980-02-15 | 1981-10-28 | Glaxo Group Ltd | Androstane carbothioate compound |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| GB9313650D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
-
1996
- 1996-10-24 GB GBGB9622173.4A patent/GB9622173D0/en active Pending
-
1997
- 1997-10-23 AT AT97909496T patent/ATE240345T1/de not_active IP Right Cessation
- 1997-10-23 DK DK97909496T patent/DK0937100T3/da active
- 1997-10-23 CA CA002269134A patent/CA2269134C/en not_active Expired - Fee Related
- 1997-10-23 US US09/284,245 patent/US6406718B1/en not_active Expired - Fee Related
- 1997-10-23 JP JP10519130A patent/JP2001502350A/ja not_active Withdrawn
- 1997-10-23 EP EP97909496A patent/EP0937100B1/en not_active Expired - Lifetime
- 1997-10-23 PT PT97909496T patent/PT937100E/pt unknown
- 1997-10-23 AU AU47171/97A patent/AU4717197A/en not_active Abandoned
- 1997-10-23 WO PCT/GB1997/002929 patent/WO1998017676A1/en active IP Right Grant
- 1997-10-23 DE DE69722023T patent/DE69722023T2/de not_active Expired - Lifetime
- 1997-10-23 ES ES97909496T patent/ES2198555T3/es not_active Expired - Lifetime
-
1998
- 1998-04-28 PE PE1998000323A patent/PE68099A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB9622173D0 (en) | 1996-12-18 |
| ES2198555T3 (es) | 2004-02-01 |
| CA2269134C (en) | 2007-01-09 |
| WO1998017676A1 (en) | 1998-04-30 |
| PT937100E (pt) | 2003-09-30 |
| CA2269134A1 (en) | 1998-04-30 |
| JP2001502350A (ja) | 2001-02-20 |
| DE69722023D1 (de) | 2003-06-18 |
| ATE240345T1 (de) | 2003-05-15 |
| EP0937100A1 (en) | 1999-08-25 |
| US6406718B1 (en) | 2002-06-18 |
| AU4717197A (en) | 1998-05-15 |
| DE69722023T2 (de) | 2004-04-08 |
| EP0937100B1 (en) | 2003-05-14 |
| DK0937100T3 (da) | 2003-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE68099A1 (es) | Productos particulados | |
| CA2277913A1 (en) | New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof | |
| TR199902880T2 (xx) | �nce par�alanm�� kristal budesonid par�ac�klar� i�eren kompozisyon | |
| PL334493A1 (en) | Novel inhalable preparation of 0.28 to 0.38 g/ml bulk density containing budesonide | |
| CA2277890A1 (en) | New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol | |
| FR2407018A1 (es) | ||
| GB174891A (en) | Process for producing finely granulated compounds | |
| CA2277891A1 (en) | New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof | |
| ES519919A0 (es) | Procedimiento para la preparacion de un agente limpiador en forma de aerosol. | |
| TW343165B (en) | Process for atomizing a dispersible liquid material or a mixture of dispersible liquid materials | |
| IT8420304A0 (it) | Prodotti antimicotici aventi un'elevata cessione di sostanza attiva sotto forma di soluzione edi prodotto da spruzzare. | |
| AU543358B2 (en) | Detergent containing bicarbonate particles | |
| CA2098224A1 (en) | Process for Making Dry Coffee Aroma Oil | |
| HUT56479A (en) | Process for producing compositions comprising plant protectives with controlled release of active ingredient and/or plant nourishing materials | |
| DE69101792D1 (de) | Feste und poröse Einzeldosisform, enthaltend Perlpartikel und Verfahren zu ihrer Herstellung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |